There is light once again at the end of the tunnel for UCB S.A.'s Bimzelx to finally enter the highly competitive US psoriasis market and the Belgian group is also making good clinical progress in other indications, reviving hopes that the IL-17A and IL-17F inhibitor will eventually reach blockbuster status.
UCB Makes Another Push To Get Bimzelx Over Finishing Line In US
Potential Blockbuster Resubmitted For Psoriasis
The Belgian group was stunned by an FDA rejection in May for its dual IL-17A and IL-17F inhibitor and although the refiling is complete, UCB may still have to wait six months to get Bimzelx into the all-important US psoriasis market.
More from Dermatological
More from Therapy Areas
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.